aza-TdC
Phase 1Small molecule
aza-TdC is one of 20 small molecule programs targeting Neoplasms. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
29 competitors in Neoplasms
#DrugCompanyPhaseTrials
1Alimta
SShawn Eagle
Phase 3
Fludara
SanofiPhase 2
Camptosar
PfizerPhase 2
Verzenio
Eli LillyPhase 2
Gemzar
Johnson & JohnsonPhase 2
Cyramza
Eli LillyPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Taxotere
AAvyxa
Phase 2
Navelbine
PPierre Fabre Medicament
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for aza-TdC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNational Cancer Institute (NCI)